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Background: Alzheimer’s disease impairs brain 
circulation by inducing blood clotting.  
Results: Amyloid  peptide in Alzheimer’s 
brain tissue increases platelet intracellular Ca
2+
, 
dense granule secretion and ADP release. 
Conclusion: Amyloid  peptide induces blood 
clotting by directly activating platelets. 
Significance: This study explains the link 
between Alzheimer’s disease and poor brain 
blood supply and suggests new treatments for 
this disease. 
 
ABSTRACT 
Alzheimer’s disease is a highly 
debilitating disease of the central nervous 
system associated with the accumulation of 
amyloid β (Aβ) peptides in the brain. Besides 
their cytotoxic effect on neurons, Aβ peptides 
are thought to be responsible for the 
atherothrombotic complications associated with 
Alzheimer’s disease, which are collectively 
known as cerebrovascular disease. In this study, 
we have investigated the effect of Aβ peptides 
on human platelet signal transduction and 
function. Using live cell Ca
2+
 
spectrofluorimetry, we discovered that Aβ 
peptides induce an increase in platelet 
intracellular Ca
2+
 similar to physiological 
agonists. This increase of intracellular Ca
2+
 
stimulates - and dense granules secretion and 
leads to the release of the secondary agonist 
ADP. Released ADP acts in an autocrine 
manner as a stimulant for critical signaling 
pathways leading to the activation of platelets, 
which include the activation of the protein 
kinases Syk, protein kinase C, Akt, and 
mitogen-activated protein kinases. Ca
2+
-
dependent release of ADP is also responsible for 
the activation of the small GTPase Rap1b and 
the fibrinogen receptor integrin αIIbβ3, which 
leads to increased platelet aggregation and 
increased thrombus formation in human whole 
blood. Our discoveries complement existing 
understanding of the role of Aβ peptides in 
cerebrovascular dementia and suggest the 
inhibition of ADP signaling as a potential 
therapeutic avenue in the treatment of 
Alzheimer’s disease.  
 
INTRODUCTION 
Abnormal metabolism of the amyloid 
precursor protein (APP) through the 
amyloidogenic pathway results in the 
accumulation of heterogeneous amyloid β (A 
peptides (40-42 amino acids) in the central 
nervous system, causing the onset of 
Alzheimer’s disease (AD) (1,2). Amyloid 
peptides accumulate also in the cerebrovascular 
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system of AD patients and play a role in the 
onset and progression of cerebrovascular 
diseases, such as stroke and cerebral amyloid 
angiopathy (CAA) (3). Amyloid A peptides are 
responsible for the prothrombotic state described 
in several AD patients, where increased clot 
formation, decreased fibrinolysis, and elevated 
levels of coagulation factors are responsible for 
reduced blood flow to the brain, 
neuroinflammation and ultimately 
neurodegeneration (4). Platelets are the major 
source of amyloid peptides found in plasma. 
Platelets express the amyloid precursor protein 
APP and the enzymatic machinery responsible 
for its metabolism and for the generation of Aβ 
peptides (5-7). In physiological conditions 
platelets metabolize APP through the non-
amyloidogenic pathway: -secretase is activated 
by Ca
2+ 
and calmodulin (8) and releases soluble 
APP (sAPP) which regulates thrombosis and 
hemostasis in vivo (9). In AD, however,  and 
-secretases activity increases, and APP is 
metabolized to produce amyloid  peptides, 
which leads to alteration of the APP content of 
platelets (10). Soluble APP fragments and A 
peptides are stored in platelet granules and 
released upon stimulation with physiological 
agonists (11). Several studies suggested that 
platelet-derived A peptides may represent a 
reliable peripheral biomarker of AD (12,13). 
Abnormalities in platelet membrane fluidity and 
secretase activity, as well as increased APP level 
have been documented in platelets from AD 
patients (14).  
It has become increasingly clear that A 
peptides directly activate platelets. Herczenik 
and coworkers showed that misfolded amyloid 
peptides induce platelet activation and 
aggregation through two different pathways 
initiated by CD36 or GPIb, respectively (15). A 
short peptide corresponding to the biologically 
active sequence of AA25-35) (16,17) is able 
to activate human platelets and potentiate 
platelet aggregation induced by low doses of 
collagen, ADP and thrombin through 
phosphoinositide 3-kinase (PI3K) and p38 
mitogen-activated protein kinase (MAPK)-
dependent pathway (18,19). Sonkar et al. have 
recently demonstrated that A25-35 stimulates 
platelet activation through RhoA dependent 
modulation of actomyosin organization (20). 
Moreover, immobilized A peptides are able to 
induce platelet adhesion and activation of 
intracellular signaling pathway, and to fasten 
spreading over collagen (21). Despite these 
reports, the exact mechanism responsible for A 
peptides-dependent activation of platelets 
remains elusive.   
In the present study, we investigated 
further the molecular mechanism of A-induced 
platelet activation. One of the most interesting 
hypotheses on the mechanism for A toxicity is 
based on the ability of the peptides to form 
cation permeable pores in the cellular 
membranes, which ultimately results in 
membrane depolarization, Ca
2+
 leakage, and 
disruption of ionic homeostasis (22,23). Because 
of the effect of A peptides on intracellular Ca2+ 
in other cell types (24), we investigated the 
effect of this protein on platelet intracellular 
Ca
2+
 homeostasis. We demonstrated that A 
peptides are directly responsible for Ca
2+
 
mobilization and granule secretion. The 
resulting release of ADP stimulates canonical 
signaling pathways, leading to activation of 
protein kinase C (PKC), PI3K, mitogen-
activated protein kinases p38MAPK and 
extracellular signal-regulated kinase (ERK) as 
well as tyrosine kinases. These events support 
platelet aggregation and thrombus formation in 
human whole blood under physiological shear 
stress. Taken together, our data unequivocally 
identify Ca
2+
-dependent release of ADP as the 
molecular mechanism underlying the pro-
thrombotic effect of A peptides and further 
clarifies the link between AD and 
cerebrovascular disease. 
 
EXPERIMENTAL PROCEDURES 
 
Materials 
A25-35, bovine serum albumin (BSA), 
dimethylsulfoxide (DMSO), prostaglandin E1, 
indomethacin, apyrase grade I and VII, collagen 
type I, leupeptin, aprotinin; BAPTA and calcein 
AM (green) were purchased from Sigma-
Aldrich (Milan, Italy). The rabbit polyclonal 
Abs against Rap1 (121), Syk (N19) and the mAb 
anti-tubulin (DM1A) were from Santa Cruz 
Biotechnology (Santa Cruz, US). Anti- phospho-
Akt(S473), anti-phospho-
p38MAPK(T180/Y182), anti-phospho-
ERK1/2(T202/Y204), anti-phospho-MLC(S19), 
and anti-PKC phospho-substrates were from 
Cell Signaling Technology (Danvers, US). 
Appropriate peroxidase-conjugated anti-IgG 
Abs were from Bio-Rad. The enhanced 
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chemiluminescence (ECL) substrate and Fura 2-
AM were from Millipore (Vimodrone, Italy). 
FITC-labeled fibrinogen was from Molecular 
Probes (Eugene, US). FITC-conjugated human 
P-selectin was from Beckman Coulter 
(Pasadena, US).  ATP determination kit was 
from Biaffin (Kasser, Germany). 
 
Preparation of washed human platelets 
Human platelets were obtained from 
healthy volunteers essentially as previously 
described with minor modifications (25). 
Briefly, whole blood in citric 
acid/citrate/dextrose (152 mM sodium citrate, 
130 mM citric acid, 112 mM glucose) was 
centrifuged at 120 × g for 10 min at room 
temperature. Apyrase grade I (0.2 units/ml), 
prostaglandin E1 (1 μM), and indomethacin (10 
M) were then added to the platelet-rich plasma 
(PRP). Platelets were recovered by 
centrifugation at 720 × g for 15 min, washed 
with 10 ml of PIPES buffer (20 mM PIPES, 136 
mM NaCl, pH 6.5), and finally gently 
resuspended in HEPES buffer (10 mM HEPES, 
137 mM NaCl, 2.9 mM KCl, 12 mM NaHCO3, 
pH 7.4). The cell count was typically adjusted to 
5 × 10
8
 platelets/ml unless otherwise stated. 
 
Analysis of platelet activation 
Unless differently stated, platelet samples 
were typically stimulated with 10-20 M A25-35 
or 0.1 U/ml thrombin as a control. Aggregation 
of platelets (2 × 10
8
 platelets/ml, 0.25 ml) was 
monitored continuously in a Born 
lumiaggregometer up to 5 minutes. Rap1b 
activation was analyzed by a pull down assay 
using the GST-tagged Rap-binding domain of 
RalGDS (GST–RalGDSRBD) essentially as 
described previously, and precipitated active 
Rap1b was identified by immunoblotting with 
an anti-Rap1 antibody (26). Measurement of 
cytosolic Ca
2+
 was performed on 0.4 ml samples 
of Fura-2AM-loaded platelets under gentle 
stirring in a PerkinElmer Life Sciences LS3 
spectrofluorimeter in the presence of 1mM 
CaCl2, or 2mM EGTA, according to a 
previously published procedure (27). For 
analysis of protein phosphorylation, identical 
amounts of proteins from whole platelet lysates 
were separated by SDS-PAGE on 5-15% or 10-
20% acrylamide gradient gels, and transferred to 
PVDF. Immunoblotting analysis was performed 
as previously described (28), using the following 
antibodies and dilutions: anti-Syk (N-19); anti-
phospho-Akt (S473), anti-phospho-p38MAPK 
(T180/Y182), anti-phospho-ERK1/2 
(T202/Y204), and anti-phospho-MLC 
(S19):1:500; anti-PKC phospho-substrates, anti-
tubulin (DM1A), and anti-Rap1 (121): 1:1000.  
Reactive proteins were visualized with a 
chemiluminescence reaction. All of the 
immunoblots are representative of at least 3 
different experiments giving similar results.  
 
Flow cytometry  
Samples of washed platelets (10
6
 cells in 
0.05 ml of HEPES buffer containing 1 mM 
CaCl2 and 1 mM MgCl2 and 0.2% BSA), 
untreated or activated with different doses of 
Aβ25-35 were labeled for 10 minutes at room 
temperature with different specific antibodies: 
Fluorescein isothiocyanate (FITC)-conjugated 
anti-P-selectin, or FITC-conjugated fibrinogen. 
Reaction was stopped by diluting samples with 
0.45 ml HEPES buffer. Samples were 
immediately analyzed by flow cytometry using a 
FACSCalibur instrument equipped with 
CellQuest Pro software (BD Bioscience, Milan 
Italy). Data analyses were performed using 
FlowJo 7.6.1 software (Tree Star Inc., Ashland, 
US). 
 
Measurement of [
14
C]serotonin secretion and 
ATP/ADP release 
Agonist-induced release of 
[
14
C]serotonin from metabolically labeled 
platelets was performed as previously described 
(27). Platelet secretion was determined by 
measuring the release of ATP by adding 
luciferin-luciferase reagent. Briefly, 5×10
8
/ml 
(0.3ml) were stimulated with the indicated 
concentrations of A25-35, and reactions were 
stopped by adding 10mM EDTA. Cells were 
spun down and 50 l of supernatant were 
analyzed with the ATP determination kit 
(Biaffin, Kasser, Germany) following 
manufacture’s instruction. 
 
Thrombus formation assay 
The Bioflux200 system (Fluxion, South 
San Francisco, US) was used to analyze 
thrombus formation in human whole blood 
under flow essentially as previously described 
(29). Microchannels were coated 30 minutes 
with 1mg/ml collagen I (monomeric collagen 
from calf skin), before blocking with 0.5% 
bovine serum albumin and washing with 
modified Tyrode’s buffer. Platelet-rich plasma 
(PRP) was isolated from blood by centrifugation 
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(200×g, 15 min) and incubated for 1 hour with 
Calcein™ (5μg/ml) at 37°C to facilitate 
thrombus visualization in whole blood. PRP was 
then added to the red blood cell fraction to 
reconstitute whole blood with physiological 
blood cell density (including platelets) and 
thrombus formation (on collagen) were 
visualized by fluorescence microscopy. Where 
indicated, 20 M A25-35 and/or 2U/ml apyrase 
was added to PRP 10 minutes before the start of 
the flow assay. Platelet adhesion under flow 
conditions was tested on collagen I (shear rate = 
1000 sec
-1
). Representative pictures were taken 
at time 10 minutes and surface area coverage 
was measured using Bioflux200 Software 
(version 2.4). 
 
Statistical analysis 
Data are expressed throughout as mean 
± SEM. The results were analyzed by t-test (for 
comparisons of two groups) or one-way 
ANOVA with Bonferroni post-test (for multiple 
comparisons). 
 
RESULTS 
A25-35 induces intracellular Ca
2+
 increase and 
granule release 
Several studies demonstrate that the 
toxicity of Apeptides resides in the ability to 
form cation pores permeable to Ca
2+
, which 
causes membrane depolarization (22). The 
ability of forming ionic pores has been 
demonstrated for amyloid peptides of different 
length, including the short A25-35 peptide (30). 
Notably, the A25-35 is regarded as the functional 
domain responsible for the neurotoxic properties 
of Apeptides, of which it represents the 
biologically active region (16). Therefore A25-35 
has been widely used to investigate the 
biological properties of Apeptides in different 
cell types including platelets (18-21).  
In this study, we analyzed the direct 
effect of A25-35 on Ca
2+ 
mobilization in washed 
human platelets labeled with Fura-2AM, both in 
the presence and in the absence of extracellular 
Ca
2+
. Representative traces reported in Figure 
1A show platelet Ca
2+
 movements in the 
presence of 1mM extracellular CaCl2 upon 
stimulation with thrombin or A25-35. 20M 
A25-35 induces a slow increase in Ca
2+
 with a 
kinetic profile different from the spike observed 
in thrombin-stimulated platelets. Pretreatment of 
platelets with EGTA, which chelates 
extracellular Ca
2+
, completely abolishes Ca
2+
 
movements. Quantitative analysis shown in 
Figure 1B reveals that A25-35 promotes a 
statistically significant increase in intracellular 
Ca
2+
. Recent evidence suggested a pivotal role 
for RhoA in platelet activation induced by A25-
35 and the activity of Rho-associated coiled-coil 
protein kinase (ROCK) was found necessary for 
A25-35-induced cytoskeletal rearrangements and 
aggregation (20). Therefore, we tested the effect 
of the ROCK inhibitor Y27632 on A25-35-
induced increase in intracellular Ca
2+
 and 
demonstrated that Ca
2+
 influx is upstream of 
RhoA activation in the signaling event 
stimulated by A25-35 (Figure 1C). In addition, 
pre-incubation of platelets with the ADP-
degrading enzyme apyrase does not significantly 
affect intracellular Ca
2+
 movements induced by 
A25-35, suggesting that this effect of A25-35 is 
not ADP-dependent (Figure 1C).  
Platelet granule secretion was next analyzed. 
In the presence of 1mM CaCl2 A25-35 induces a 
dose-dependent -granule release, measured as 
P-selectin exposure, and dense granules release, 
measured as 
14
C-serotonin secretion (Figure 2). 
Densegranule secretion is significantly reduced 
in the absence of extracellular CaCl2 suggesting 
that A25-35-induced Ca
2+
 influx in platelets is 
required for dense granule release. Platelet dense 
granule release was also evaluated by measuring 
the extracellular accumulation of ADP/ATP 
using the luciferin/luciferase assay. We found 
that platelets at the physiological density of 5 x 
10
8
/ml release ADP at the concentration of 
0.146 ± 0.1 and 0.184 ± 0.13 M in response to 
10 M and 20M A25-35, respectively. 
 
A25-35 stimulates activatory signaling 
pathways in an ADP-dependent manner  
It has been demonstrated that A25-35 is able 
to activate intracellular signaling pathways 
initiating a cascade of phosphorylation of 
different effectors, namely mitogen activated 
protein kinases p38MAPK and ERK1/2, PI3K 
and PKC (18,19). In light of the ability of A25-
35 to promote granule secretion and ADP release, 
we investigated the possible role of ADP in 
platelet activation induced by A25-35. 
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Immunoblotting analysis with phospho-specific 
antibodies shows that A25-35 induces a time-
dependent phosphorylation of several key 
signaling proteins. These substrates include the 
MAPKs p38MAPK and ERK1/2, the PI3K-
regulated kinase Akt, and the PKC substrate 
pleckstrin (Figure 3A). Moreover, A25-35 
promotes the rapid and robust tyrosine 
phosphorylation of several proteins as identified 
using the phosphotyrosine-specific antibody 
4G10 (Figure 3B). Phospho-specific bands in 
Figure 3B include a substrate with an apparent 
molecular mass of about 70 kDa, which is likely 
to be the non-receptor tyrosine kinase Syk. In 
fact, the A25-35-dependent phosphorylation of 
Syk has been confirmed by immunoprecipitation 
experiments (Figure 3C). Interestingly, A25-35-
induced phosphorylation of these substrates is 
completely prevented in the presence of the 
ADP scavenger apyrase, indicating that the 
positive signaling initiated by secreted ADP 
plays a critical role in A25-35-induced platelet 
activation. Accordingly to previous evidence 
(20), A25-35 also induces phosphorylation of the 
Ca
2+
-regulated myosin light chain (MLC), 
which, however, is only partially reduced by 
pre-incubation of platelets with apyrase (Figure 
3D), suggesting that, in contrast to the molecular 
events described above, MLC phosphorylation 
is at least partially promoted in an ADP- and 
granule secretion-independent manner. 
Flow cytometry analysis of FITC-labelled 
fibrinogen binding to platelets demonstrates that 
A25-35 stimulates integrin αIIbβ3 inside-out 
activation in a concentration-dependent manner 
(Figure 4). Next we analyzed the activation of 
the small GTPase Rap1b, which is an essential 
regulator of integrin inside-out signaling 
(31,32). Using a pull down assay we 
demonstrated that A25-35 dose dependently 
stimulates Rap1b activation (Figure 5A). 
Accumulation of Rap1b-GTP by A25-35 is rapid 
but transient, as it reverts after 1 minute (Figure 
5B). Remarkably, the activation of Rap1b by 
A25-35 is independent of integrin αIIbβ3 since it 
is not modified by pre-incubation with RGDS, 
but it is completely abolished in the presence of 
apyrase (Figure 5C), suggesting that the release 
of ADP is the molecular mechanism underlying 
the regulation of this GTPase by A25-35.  
 
 
Endogenous ADP release is necessary for A25-
35-induced platelet aggregation and increase 
thrombus formation under flow 
We next analyzed the ability of Aβ25-35 to 
stimulate platelet aggregation and investigated 
its mechanism of action. Platelet aggregation 
was induced by different concentrations of A25-
35 under constant stirring in a Born 
lumiaggregometer in the presence of 1 mM 
extracellular Ca
2+
 (Figure 6A). A25-35 dose 
dependently induces platelet aggregation. A25-
35-induced aggregation is mediated by integrin 
activation since it is blocked by treatment with 
RGDS peptide (data not shown) and depends on 
Ca
2+
 as it is strongly reduced in the absence of 
extracellular Ca
2+
 and by preincubation with 
intracellular Ca
2+
 chelator BAPTA (Figure 6B). 
The role of A25-35-induced ADP secretion was 
tested using the ADP degrading enzyme 
apyrase, which strongly reduces platelet 
aggregation induced by A25-35 (Figure 6C). As a 
control, we assessed the release of α- and dense 
granules in the presence of apyrase (Figure 6D 
and E, respectively). Neither were affected by 
apyrase, suggesting that the regulation of 
platelet degranulation is upstream of the effect 
on platelet aggregation.   
We have previously demonstrated that 
platelets are able to adhere on immobilized 
Apeptides in static condition and to fasten 
spreading over collagen (21). Here, we 
evaluated the ability of A25-35 to potentiate 
platelet adhesion to collagen and thrombus 
formation under physiological flow conditions. 
Platelets from human whole blood were 
selectively labelled with calcein AM and the 
formation of thrombi under arterial shear stress 
(1000 sec
-1
) was assessed as previously 
described (29). As shown in Figure 7A, platelet 
adhesion and thrombus formation on collagen-
coated surfaces is significantly increased by 
collagen co-incubation with 10µM A25-35 
during coating. Surprisingly, addition of A25-35 
directly to blood does not increase thrombus 
adhesion on collagen-coated surfaces (data not 
shown), possibly due to increased platelet-
platelet interaction rather than potentiation of 
adhesion to absorbed collagen. Pre-treatments of 
platelets with apyrase ablates the increase in 
thrombus formation observed in our experiments 
(Figure 7B), which further suggests the 
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importance of ADP release in the potentiatory 
effect of A25-35.  
 
DISCUSSION 
 
The ability of A peptides to promote 
activation and adhesion of platelets has been 
previously reported by our group and others (18-
21), and is likely to significantly contribute to 
the development and progression of 
cerebrovascular diseases associated with AD. In 
the present study, we investigated the molecular 
mechanism underlying the activation of platelets 
by Aβ peptides, and we demonstrated for the 
first time the crucial and hierarchical role of 
intracellular Ca
2+
 increase and ADP secretion. 
We propose that Ca
2+
-mediated dense granule 
release and secretion of ADP is an early event in 
platelet stimulation by A25-35, and that secreted 
ADP is the major player in the stimulation and 
propagation of platelet activation. We 
demonstrated that pre-incubation of platelets 
with ADP scavenging enzyme apyrase strongly 
reduce A25-35-induced platelet aggregation and 
potentiation of thrombus formation. Activation 
of the small GTPase Rap1b and consequentially 
integrin IIb3 stimulation, are also dependent on 
ADP. Moreover, A25-35-induced 
phosphorylation and activation of signaling 
protein Syk, PKC, PI3K, and mitogen activated 
kinases p38MAPK and ERK1/2 dependent on 
ADP, since are completely abolished in the 
presence of apyrase. Our current data reinforce 
our previous studies showing that although static 
platelet adhesion to immobilized A peptides is 
not dependent on ADP, even in these conditions 
the release of ADP reinforces the activation of 
intracellular signaling pathways (21).  
In our experiments, we detected a slow 
and significant increase of the intracellular Ca
2+
 
concentration in platelets treated with A25-35 
peptide, a widely used tool representing the 
biologically active portion of both the naturally 
generated fibrillogenic peptide A1-40 and A1-42 
peptides). Our data clearly show that A25-35 
induces a significant increase in intracellular 
Ca
2+
, which is necessary for the stimulation of 
A25-35-induced - and dense granule release, 
and is critical for platelet aggregation. This 
observation is consistent with previous 
hypotheses that A peptides can generate pores 
in the plasma membrane of cells leading to Ca
2+
  
influx from the extracellular space (22-23;33). 
However, it remains unclear, at the present, 
whether A generates pores in the plasma 
membrane of human platelets to allow Ca
2+
 
influx or whether it regulates pre-existing Ca
2+
 
channel.  Hence, the molecular mechanisms 
linking A peptides to platelet intracellular Ca2+ 
increase remains elusive and will require further 
investigation.  
We documented the activation of PKC in 
A-stimulated platelets, as revealed by the 
phosphorylation analysis of the intracellular 
protein pleckstrin (34). The activation of PKC 
(which is usually downstream of PLC activation, 
IP3 generation and release of Ca
2+
 from 
intracellular stores, 35) is not an early event in 
platelet activation by Apeptide. In fact, 
differently to what we observed for the 
intracellular Ca
2+
 increase, the complete 
inhibition of pleckstrin phosphorylation by the 
ADP scavenger apyrase demonstrates that 
PLC/PKC activation is secondary to granule 
release. These observations are in partial 
disagreement with a previous study indicating 
that inhibition of PKC by Ro318220 prevents 
A-induced Ca
2+
 increase (19). Although it 
is difficult to understand the reason for this 
discrepancy, we would like to highlight that the 
inhibition of the Ca
2+ 
spike shown by those 
authors is only partial, which is not excluding 
the possibility of a double source for the 
intracellular Ca
2+ 
increase in response to A25-35 
(i.e. partially from membrane permeabilization 
and partially from intracellular store release). 
Moreover, the limited specificity of Ro318220 
could be responsible for some misinterpretation 
of the data in the above study (36). 
Recently, an important early role for the 
RhoA-activated protein kinase ROCK in platelet 
activation by A has been proposed (20). 
Although the ROCK inhibitor Y27632 did not 
inhibit the Ca
2+
 wave induced by A peptides, 
our data presented here are not in disagreement 
with this publication. In fact, although we prove 
that ROCK is not responsible for the initial 
increase in intracellular Ca
2+
, our data do not 
exclude that ROCK is indeed stimulated by A 
peptides and plays an important role in the 
resulting platelet activation. This is in agreement 
with our data showing that MLC (a known 
substrate for ROCK) is phosphorylated in 
response to platelet incubation with A.       
One of the strengths of our data is in the 
identification of a strong intracellular Ca
2+
-
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dependent stimulation of granules secretion in 
the presence of A peptides. Interestingly, upon 
stimulation with A peptides, MLC is rapidly 
phosphorylated, which is likely to result in the 
reorganization of actomyosin contractility and 
the release of α- and dense granules (37). 
Interestingly, the inhibition of ADP in our cell 
signaling experiments completely abolished the 
phosphorylation of all intracellular targets 
analyzed yet it only marginally reduced the 
phosphorylation of MLC, suggesting that this 
cellular event occurs upstream of granule 
secretion, and may be directly driven by 
intracellular Ca
2+
  increase. On the other hand, 
the activation of the other protein kinases 
investigated herein and their signaling is likely 
to be a consequence of granule and ADP release.  
Taken together, our data suggest the 
centrality of ADP in the stimulation of platelet 
activation, aggregation and thrombus formation 
by A peptides. As shown in figure 8, we 
propose a signaling model for A peptides 
stimulation of platelet responses, in which 
extracellular Ca
2+
 influx into the platelet leads to 
dense granules release and ADP secretion, and 
consequent ADP-dependent signaling through 
several intracellular protein kinase pathways and 
activation of Rap1b. As previously shown (38), 
the activation of Rap1b leads to integrin inside-
out signaling and stimulates fibrinogen binding 
at the base of key physiological phenomena such 
as platelet aggregation and thrombus formation. 
To our knowledge, our novel observations 
clarify the pathological role of A peptides in 
cerebrovascular disease and indicate that platelet 
ADP receptors are novel targets for the 
treatment of vascular complications of AD.  
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FIGURE LEGENDS 
 
Figure 1. A25-35 induces Ca
2+
 inward in washed platelets  
Platelets (2×10
8
/ml, 0.4ml) were loaded with Fura-2AM (3M, 40 minutes) and stimulated with 
1U/ml thrombin or 20M A25-35 in the presence of 1mM extracellular CaCl2 or 2mM EGTA. Traces 
of Ca
2+
 mobilization are representative of three different experiments (A). Histograms show the 
quantification of the intracellular concentration of Ca
2+
 4 minutes after stimulation (grey bar: 1mM 
extracellular CaCl2; white bar: 2mM EGTA) (B). C) Fura-2AM loaded platelets were stimulated with 
20µM Aβ25-35 in the presence of 1mM extracellular CaCl2. Where indicated platelets were 
preincubated with 20 µM Y27632 or 2U/ml apyrase for 10 minutes. Histograms show the 
quantification of the intracellular concentration of Ca
2+
 4 minutes after stimulation. Statistical analysis 
was performed by one-way ANOVA with Bonferroni post-test, n=3, *: p<0.05, ***: p<0.001, and it is 
referred to unstimulated sample 
 
Figure 2. A25-35 induces dose-dependent - and dense granule secretion  
Flow cytometry analysis of P-selectin exposure in platelets stimulated with the indicated 
concentrations of A25-35 (M) is shown in (A). Data are expressed as percent of positive cells, and are 
the mean ± SEM of 4 experiments. Concentration-response analysis of A25-35 -induced release of 
[
14
C]serotonin from washed human platelets, in the presence (1mM CaCl2: black bar) or in the absence 
(2mM EGTA: white bar) of extracellular Ca
2+
 (B). The release of serotonin in the supernatant is 
expressed as percentage of the total incorporated radioactivity upon subtraction of the values 
measured in the supernatant of resting platelets. Data are expressed as mean ± SEM of three to five 
different experiments. Statistical analysis was performed by t-test, *: p< 0.05, **: p<0.01. 
Figure 3. A25-35-induced signaling pathway activation requires ADP release 
Washed platelets (5×10
8
/ml, 0.1ml) were treated with 10 M A25-35 for the indicated time (A, B and 
D) or 2 minutes (C). Where indicated platelets were incubated with 2U/ml apyrase grade VII 
(apyrase) or buffer (none) for 10 minutes at 37°C prior the addition of A25-35. Total proteins were 
separated by SDS-PAGE and protein phosphorylation was analyzed by immunoblotting with the 
indicated antibodies: A) anti-P-Akt; anti-PKC phospho-substrates (P-pleckstrin); anti-P-ERK1/2 , 
anti-P-p38MAPK, and anti-tubulin for equal loading; B) anti-P-Tyr (4G10), D) anti-P-MLC and anti-
tubulin for equal loading.  In C), washed platelets (1×10
9
/ml) treated as described above were lysed 
and Syk was immunoprecipitated using a specific antibody. Phosphorylation of immunoprecipitated 
Syk was evaluated with antibody anti-P-tyrosine 4G10. The level of immunoprecipitated protein was 
confirmed by immunoblotting with anti-Syk antibody. Data shown here are representative of three 
independent experiments. 
 
Figure 4. A25-35 induces integrin IIb3 activation and fibrinogen-binding  
Washed platelets (2×10
7
/ml, 0.05ml) were treated with Tyrode’s buffer (none) or 20M A25-35. 
FITC-conjugated fibrinogen (5l) was added to the platelet suspensions and incubated for 30 minutes 
before dilution with 0.45ml of HEPES buffer. Fibrinogen binding was quantified by flow cytometry. 
Representative dot plots of the fluorescent labelling (FL1-H: FBN FITC) over forward scattering 
(FSC) are shown in A). In B), the percentage of fibrinogen positive human platelets stimulated with 
the indicated concentrations of A25-35 are presented. Data are expressed as mean ± SEM of three 
different experiments.  
 
Figure 5. A25-35 induces Rap1b activation dependently on ADP release 
Rap1b activation (Rap1b-GTP) was evaluated by activation state-dependent pull-down assay (GST–
RalGDSRBD) followed by immunoblotting with anti-Rap1b antibody. Washed platelets were 
stimulated with different concentrations of A25-35 as indicated for 2 minutes (A), or with 10 M A25-
35 for the different time (B) or with 10 M A25-35 for 2 minutes (C). In C), platelets were preatreated 
for 10 minutes with 2U/ml apyrase, 10M RGDS, or HEPES buffer (none) before stimulation with 
A25-35. Platelets were then lysed, and 0.5 ml of lysates were incubated with GST–RalGDSRBD. The 
levels of active precipitated Rap1b were tested by immunoblotting (Rap1b-GTP). Upper panels 
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represent the immunoblot of the pull-down samples. Lower panels show the amount of the total 
protein (Rap1b). Data shown here are representative of three independent experiments. 
 
Figure 6. A25-35-induced platelet aggregation depends on Ca
2+
 mobilization and ADP release 
Human washed platelets (3×10
8
/ml) were stimulated with different concentrations of A25-35 (as 
indicated) in the presence of 1mM extracellular Ca
2+
 (A, B and C). In B), platelets were also tested in 
the absence of extracellular Ca
2+
 (none) or preincubated for 2 minutes with 30M BAPTA. In C) 
platelets were preincubated for 10 minutes with 2U/ml apyrase. Aggregation was monitored as 
increase of light transmission up to 5 minutes. Traces in the figure are representative of 3 or more 
independent experiments. In D) flow cytometry analysis of P-selectin exposure in platelets stimulated 
with 10 M A25-35 preincubated with 2U/ml apyrase (apyrase: white bar) or buffer (none: grey bar) is 
shown. In E) A25-35 -induced release of [
14
C]serotonin from washed human platelets, in the presence 
(white bar) or in the absence (grey bar) of 2U/ml apyrase is shown. The release of serotonin in the 
supernatant is expressed as percentage of the total incorporated radioactivity upon subtraction of the 
values measured in the supernatant of resting platelets. For both D) and E), data are expressed as 
percent of positive cells, and are the mean ± SEM of 3 experiments.  
 
Figure 7. Aβ25-35 increases thrombus formation in whole blood under physiological flow 
conditions in an ADP-dependent manner  
Human platelet-rich plasma (PRP) was isolated from anticoagulated blood (citrate) and incubated for 
1 hour with Calcein AM (5 μg/ml) at 37°C. After reconstitution of whole blood by mixing labelled 
PRP and the red blood cell fraction, thrombus formation was monitored under physiological shear 
stress conditions (1000 sec
-1
). Coating of the microvessel was performed for 60 minutes at 37C with 
collagen alone (1mg/ml) or collagen plus Aβ25-35 (20 µM) (A and B). Where indicated, apyrase 
(1U/ml) was added to the blood 10 minutes prior the assay (B). Both panels show a representative 
picture of the thrombi and a quantification of the surface coverage after 10 minutes of flow (mean ± 
SEM, n=4). Statistical significance of the differences was measured using a t-test for paired samples 
(* = p<0.05).  
 
Figure 8. A model for A25-35-induced platelet activation 
In the presence of extracellular Ca
2+
, A25-35 promotes mobilization of intracellular Ca
2+
, initial 
phosphorylation of MLC and consequent release of dense granules, with secretion of ADP. ADP in 
turn activates platelets through several intracellular protein kinase pathways, including tyrosine 
kinases (Tyr-K), Syk, PI3K, PKC, ERK1/2 and p38MAPK. Resulting activation of Rap1b and 
integrin IIb3 leads to platelet aggregation and thrombus formation.  
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